Pharma Infographic Sample
•
0 likes•139 views
GlaxoSmithKline is focused on developing HIV therapies that minimize cumulative drug exposure for patients who must endure lifelong antiretroviral treatment. It believes the potency, safety and resistance barrier of dolutegravir combined with the efficacy, safety and tolerability of rilpivirine from Johnson & Johnson make them ideal candidates for a two-drug HIV regimen.
Pharma Infographic Sample
- 11. GSK Focused On Minimizing Need For Cumulative Drug Exposure Glaxo is the second-largest HIV company, with revenue of about $5.2 billion versus Gilead's $12.9 billion. Long-life antiretroviral therapy that the HIV infected have to endure has created a need to minimize cumulative drug exposure. Glaxo wants to develop HIV therapies that meet that need. It believes the potency, safety and resistance barrier of dolutegravir and the efficacy, safety and tolerability of Johnson & Johnson's (NYSE:JNJ) rilpivirine make them ideal for a two-drug regimen.